Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Crystal Forms of Ziprasidone

지프라시돈의 결정형

  • 윤미희 (덕성여자대학교 화학과) ;
  • 방효춘 (덕성여자대학교 화학과) ;
  • 손영택 (덕성여자대학교 약학대학)
  • Published : 2009.04.27
Download PDF
⟨ Previous Next ⟩

Abstract

Two crystal forms of ziprasidone have been isolated by recrystallization from different organic solvents and characterized by differential scanning calorimetry, powder X-ray diffractometry and thermogravimetric analysis. It was confirmed that Form 2 has the same crystal structure as Form 1.

Keywords

References

  1. B. D. Sharma, Allotropes and polymorphs, J. Chem. Educ., 64, 404-407 (1987). https://doi.org/10.1021/ed064p404
  2. J. Bernstein, Conformational polymorphism, Stud. Org. Chem. (Amsterdam), 32(Org. Solid Statd Chem.), 471-518 (1987).
  3. M. Kitamura, Polymorphism in crystallization, Kagaku kogaku, 55, 263-264 (1991).
  4. J. Haleblian and W. McCrone, Pharmaceutical applications of polymorphism, J. Pharm. Sci., 58, (1969). https://doi.org/10.1002/jps.2600580802
  5. Y. T. Sohn, Effect of crystal form on bioavailability, J. Kor. Pharm. Sci., 34, 443-452 (2004).
  6. W. C. Kind, P. Varlashkin and C. Li, The applicability of powder x-ray diffraction to the quantification of drug substance polymorphs using a model organic system, Powder Diffr., 8, 180-187 (1993). https://doi.org/10.1017/S0885715600018157
  7. J. Bernstein, Polymorphism and the investigation of structure-property relations in organic solids, Int. Union Crystallogr. Crystallogr. Symp., 4 (Org. Cryst. Chem.), 6-26 (1991).
  8. F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Theor. Chem., 69 (Struct. Prop. Mol. Cryst.), 211-234 (1990).
  9. N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa,Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-41 (1989).
  10. E. F. Fiese and T.A. Hagen, Preformulation : In Theory and Practice of Industrial Pharmacy, L. Lachman, H. A. Lieberman and J. L. Kanig (Ed.), Third Edition, Lea and Febiger, Philadelphia, pp 176-181 (1986)
  11. H. G. Brittain and D. J. W. Grant, Effects of polymorphism and solid-state solvation on solubility and dissolution rate : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 279-330 (1999)
  12. Y. T. Sohn, Crystal forms of an angiotensin II receptor antagonist BR-A657, J. Therm. Anal. Cal., 89(3), 799-802 (2007). https://doi.org/10.1007/s10973-005-7307-2
  13. E. A. Lee and Y. T. Sohn, Crystal forms of a capsaicin derivative analgesic DA-5018, J. Therm. Anal. Cal., 93(3), 871-874 (2008). https://doi.org/10.1007/s10973-008-9076-1
  14. Y. T. Sohn and B. Y. Park, Characterization of the physicochemical properties of KR-31378, Arch. Pharm. Res., 26, 526-531 (2003). https://doi.org/10.1007/BF02976875
  15. A. Bauer-Brandl and Y. T. Sohn, Crystal modifications of cimetidine: Characterization and evaluation for manufacturing of dosage forms, Eur. J. Pharm. Biopharm., 40 (Suppl.), (1994).
  16. Y. T. Sohn, J. K. Lee and W. B. Im, Polymorphism of clarithromycin, Arch. Pharm. Res., 23, 381-384 (2000). https://doi.org/10.1007/BF02975451
  17. Y. T. Sohn and S. Y. Kim, Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids, Arch.Pharm. Res., 25, 556-559 (2002). https://doi.org/10.1007/BF02976618
  18. Y. T. Sohn and H. O. Seo, Crystal Forms of Ketorolac, Arch. Pharm. Res., 27, 357-360 (2004). https://doi.org/10.1007/BF02980073
  19. Y. T. Sohn and Y. H. Lee., Polymorphism of Doxazocin mesylate, Arch. Pharm. Res., 28, 732-737 (2005). https://doi.org/10.1007/BF02969365
  20. Y. T. Sohn and S. H. Park, Crystal Forms of Cephradine, Arch. Pharm. Res., 29, 178-182 (2006). https://doi.org/10.1007/BF02974281
  21. Y. T. Sohn and S. H. Kim, Polymorphism and pseudopolymorphism of acyclovir, Arch. Pharm. Res., 31, 231-234 (2008). https://doi.org/10.1007/s12272-001-1146-x
  22. Y. T. Sohn, Effect of polymorphism on bioavailability of amoxycillin, Yakhak Hoeji., 39, 438-443 (1995).
  23. A. Burger, Zur Interpretation von Polymorphie-untersuchungen, Acta Pharm. Technol., 28, 1-20 (1982).
  24. A. Burger and K. T. Koller, Polymorphism and pseudopolymorphism on nifedifine, Sci. Pharm., 64, (1996).
  25. A. David, E. Balogh, G. Csoka and I. Racz, Methodological aspects of examination of the polymorphism of vincristine sulfate, Sci. Pharm., 64, 311-318 (1996).
  26. M. R. Caira, M. Zanol, T. Peveri, A. Gazzaniga and F. Giordano, Structural characterization of two polymorphic forms of piroxicam pivalate, J. Pharm. Sci., 87, 1608-1614 (1998). https://doi.org/10.1021/js980059s
  27. H. G. Brittain, Methods for the characterization of polymorphs and sovates : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 227-278 (1999)